ACHV Achieve Life Sciences Inc.

7.18
-0.41  -5%
Previous Close 7.59
Open 7.45
52 Week Low 4.51488
52 Week High 28
Market Cap $25,992,916
Shares 3,617,664
Float 3,599,987
Enterprise Value $8,905,733
Volume 1,573,016
Av. Daily Volume 166,426
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Cytisine - ORCA-2
Smoking cessation
Phase 3
Phase 3
Phase 3 trial initiation announced October 7, 2020.

Latest News

  1. SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 322,500 shares of common stock in connection with the…

    SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 322,500 shares of common stock in connection with the public offering.  All of the securities are being offered by Achieve. The offering is expected to close on or about December 7, 2020, subject to the satisfaction of customary closing conditions. 

    Lake Street Capital Markets LLC is acting as the sole bookrunning manager in the offering. Maxim Group LLC is serving as the co-manager.

    Achieve intends to use the proceeds from the offering to fund its Phase 3 ORCA-2 trial, clinical research and development, as well as for working capital and general corporate purposes.

    The securities are being offered by Achieve pursuant to a registration statement on Form S-1 (File No. 333-250074) declared effective by the Securities and Exchange Commission (SEC) on December 2, 2020, and the registration statement filed by the Company with the SEC on December 2, 2020 pursuant to Rule 462(b). The offering is being made only by means of a prospectus included in the registration statement, copies of which may be obtained from: Lake Street Capital Markets LLC, Prospectus Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402 or by email at . When available, electronic copies of the final prospectus may be obtained for free by visiting the website of the SEC at http://www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Achieve, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

    About Achieve and Cytisinicline

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide. and nearly half a million deaths in the U.S. annually.1 2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the ability to complete the offering, potential exercise of the overallotment option, expected use of proceeds, potential benefits of Achieve's product candidates and platform and potential market opportunities for Achieve's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. There can be no assurance regarding the completion of the offering. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, and others described in Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and Achieve's registration statement on Form S-1 (File No. 333-250074). Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Achieve Contact

    Jason Wong



    (415) 375-3340 ext. 4

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-pricing-of-15-million-public-offering-301185305.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
  2. SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock offered in the public offering.  All of the securities are being offered by Achieve. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed…

    SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock offered in the public offering.  All of the securities are being offered by Achieve. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Lake Street Capital Markets LLC is acting as the sole bookrunning manager in the offering. Maxim Group LLC is serving as the co-manager.

    Achieve intends to use the proceeds from the offering to fund its Phase 3 ORCA-2 trial, clinical research and development, as well as for working capital and general corporate purposes.

    A registration statement on Form S-1 (File No. 333-250074) has been filed with the Securities and Exchange Commission (SEC) but has not yet become effective. Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The offering is being made only by means of a prospectus included in the registration statement, copies of which may be obtained from: Lake Street Capital Markets LLC, Prospectus Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402 or by email at . Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Achieve, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

    About Achieve and Cytisinicline

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide. and nearly half a million deaths in the U.S. annually.12  More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2  Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.  Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding its intention to conduct an offering and sale of securities, the grant of the option to purchase additional shares, the ability to complete the offering and expected use of proceeds, potential benefits of Achieve's product candidates and platform and potential market opportunities for Achieve's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  There can be no assurance regarding the completion, timing or size of the proposed offering.  Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering, and others described in Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and in the preliminary prospectus contained in the registration statement related to the proposed offering filed with the SEC on November 30, 2020. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Achieve Contact

    Jason Wong



    (415) 375-3340 ext. 4

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-proposed-public-offering-301181270.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
  3. SEATTLE and VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.

    Recent Events & Highlights

    • Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States
    • Promoted John Bencich to Chief Executive Officer and Dr. Cindy Jacobs to President
    • Presented successful results from the RAUORA, head-to-head non-inferiority clinical trial comparing cytisinicline and Chantix® (varenicline), at the Society for Research on Nicotine and Tobacco European (SRNT-E) Annual Meeting
    • Presented mechanism of action data comparing 5-HT3 receptor activity of cytisinicline vs. Chantix at SRNT-E, providing rationale for differentiated side effect profile of smoking cessation treatments
    • Announced smoking cessation Key Opinion Leader Virtual Roundtable to be held on November 17, 2020

    "With the initiation of the Phase 3 ORCA-2 trial and the breakthrough evidence, both mechanistically and clinically, in support of cytisinicline in comparison to Chantix, the third quarter of 2020 has undeniably been the most pivotal in the history of our company," commented John Bencich, Chief Executive Officer of Achieve. "Our primary focus in the coming months will be enrollment and execution of ORCA-2, while continuing to explore opportunities for commercialization and expansion into new therapeutic indications, digital health technologies, and audiences who may benefit from cytisinicline, specifically, users of vapes or e-cigarettes."

    Phase 3 ORCA-2 Trial Initiation

    Achieve's first Phase 3 ORCA-2 trial was initiated in October 2020 and will randomize 750 U.S. smokers to one of three study arms to determine the efficacy and safety of cytisinicline administered for either 6 or 12 weeks, compared to placebo. The primary endpoint is biochemically verified continuous abstinence during the last 4 weeks of treatment in the 6 and 12-week cytisinicline treatment arms compared to placebo.  Each treatment arm will be compared independently to the placebo arm and the trial will be determined to be successful if either or both of the cytisinicline treatment arms show a statistical benefit compared to placebo.

    Management Team Update

    In September, the Company announced the promotion of John Bencich to Chief Executive Officer and Dr. Cindy Jacobs to President. Mr. Bencich has been serving as Achieve's Chief Financial and Operating Officer since 2017 and will join the Board of Directors in his role. Dr. Jacobs has been serving as the Chief Medical Officer of Achieve since 2017 and will continue in her role leading the regulatory and clinical development efforts for cytisinicline. Rick Stewart will remain with Achieve as the Executive Chairman of the Board of Directors and Dr. Anthony Clark will remain in his role as Chief Scientific Officer.

    RAUORA: Significantly Fewer Adverse Events and Higher Quits Rates for Cytisinicline vs Chantix

    Final results from the New Zealand RAUORA Phase 3 non-inferiority clinical trial comparing cytisinicline to varenicline (Chantix) in Māori (indigenous New Zealanders) and whānau (family) of Māori were presented at the SRNT-E Annual Meeting in September 2020. Results showed that cytisinicline met the pre-specified non-inferiority endpoint and was trending towards superiority demonstrating a 4.29% improvement in quit rates in favor of cytisinicline. Subjects in the cytisinicline arm were approximately one and a half times more likely to have quit smoking at 6 months compared to subjects who received varenicline. Importantly, significantly fewer overall adverse events (AEs) were reported in cytisinicline-treated subjects. Of the subjects who experienced AEs (111 in the cytisinicline arm compared to 138 in the varenicline arm), there was significantly less nausea and vivid dreams.

    MOA Data Explaining Reduced Nausea and Vomiting with Cytisinicline Presented at SRNT-E

    Data presented at the SRNT-E Annual Meeting in September 2020 provides a rationale based on detailed receptor pharmacology to explain why the incidence of nausea and vomiting associated with cytisinicline appears to be consistently lower than that seen with Chantix. The preclinical study, conducted at the University of Cambridge Department of Biochemistry, was designed to examine the in vitro binding characteristics of cytisinicline compared to varenicline at the human 5-HT3 receptor. The study reported an IC50 of 0.50 mM for cytisinicline and 0.25 µM for varenicline, representing a 2000-greater fold agonist binding affinity to the 5-HT3 receptor for varenicline compared to cytisinicline.

    Virtual Smoking Cessation KOL Roundtable to be Held November 17, 2020

    Achieve announced plans to host a virtual roundtable on cytisinicline and smoking cessation on Tuesday, November 17, 2020, at 12:00PM EST. Five esteemed experts in the field of smoking cessation will discuss the ongoing ORCA-2 trial, review recent cytisinicline data, and discuss the importance of smoking cessation in the midst of the COVID-19 pandemic. Visit http://ir.achievelifesciences.com/events-and-webcasts for additional information and click here to register for the event.

    Financial Results

    As of September 30, 2020, the company's cash, cash equivalents, and restricted cash was $22.4 million. Total operating expenses for the three and nine months ended September 30, 2020 were $3.8 million and $10.0 million, respectively. Total net loss for the three and nine months ended September 30, 2020 was $3.8 million and $10.0 million, respectively.

    As of November 12, 2020, Achieve had 3,617,664 shares outstanding.

    Conference Call Details

    Achieve will host a conference call at 4:30pm Eastern time today, Thursday, November 12, 2020. To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 8047128. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

    About Achieve and Cytisinicline  

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.  

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. 

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and commercialization activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.

    Media Contact 

    Glenn Silver 

     

    (646) 871-8485 

    Investor Relations Contact 

    Jason Wong 

      

    (415) 375-3340 ext. 4 

    References 

    World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.  

    Chantix® is a registered trademark of Pfizer Inc.























    Consolidated Statements of Loss

    (In thousands, except per share and share data)

















































    Three Months Ended September 30,



    Nine Months Ended September 30,







    2020



    2019



    2020



    2019









































    Operating expenses:



















      Research and development





    1,891



    1,824



    4,535



    7,911

      General and administrative





    1,863



    1,893



    5,494



    5,408

        Total operating expenses





    3,754



    3,717



    10,029



    13,319

    Loss from operations





    (3,754)



    (3,717)



    (10,029)



    (13,319)

      Other income (expense)





    (10)



    44



    23



    118

    Net loss





    $                         (3,764)



    $                         (3,673)



    $                       (10,006)



    $                       (13,201)





















    Basic and diluted net loss per share





    $                           (1.14)



    $                           (9.07)



    $                           (4.55)



    $                         (35.96)





















    Weighted average number of basic and diluted common shares





    3,289,252



    405,012



    2,197,368



    367,103











































    Consolidated Balance Sheets

    (In thousands)



































     September 30, 



     December 31, 















    2020



    2019





















    Assets:



















      Cash, cash equivalents, short term investments and restricted cash













    $                        22,443



    $                        16,714

      Prepaid expenses and other current assets













    1,669



    670

      Property, equipment and other assets













    358



    244

      Right-of-use assets













    193



    329

      License agreement













    1,920



    2,087

      Goodwill













    1,034



    1,034

    Total assets













    $                        27,617



    $                        21,078





















    Liabilities and stockholders' equity:



















      Accounts payable and accrued liabilities













    $                          1,719



    $                          2,666

      Current portion of long-term obligations













    129



    203

      Long-term obligations













    94



    159

      Stockholders' equity













    25,675



    18,050

    Total liabilities and stockholders' equity













    $                        27,617



    $                        21,078

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-reports-financial-results-for-third-quarter-2020-and-provides-corporate-and-cytisinicline-development-update-301171373.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
  4. SEATTLE and VANCOUVER, BC, Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2020 financial results and provide an update on the cytisinicline development program on Thursday, November 12, 2020 at 4:30PM ET.

    To access the webcast, log on to the Investor Relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, you may access the live conference call by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 8047128. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days. 

    Achieve Contact 

    Jason Wong 

      

    (415) 375-3340 ext. 4 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-announce-third-quarter-2020-financial-results-and-host-conference-call-and-webcast-on-november-12-2020-301162254.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
  5. SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST

    The event will include an overview by the principal investigator of the ongoing ORCA-2 Phase 3 clinical trial of cytisinicline and provide a review of the results from the RAUORA head-to-head study of cytisinicline vs. Chantix® (varenicline). It will also feature a panel discussion, moderated by healthcare analysts Michael Higgins from Ladenburg Thalmann and Thomas Flaten from Lake Street Capital Markets, on the importance of smoking cessation in the midst of the COVID-19 pandemic, with participation from the following esteemed experts in the field of smoking cessation:

    • Nancy Rigotti, MD - Professor of Medicine, Harvard Medical School, Director of Tobacco Research & Treatment, Massachusetts General Hospital, and ORCA-2 Principal Investigator
    • Mitchell Nides, PhD - President, LA Clinical Trials LLC, ORCA-1 Principal Investigator
    • Neal Benowitz, MD - Professor of Medicine, Emeritus, University of California, San Francisco
    • Judith Prochaska, PhD, MPH - Professor of Medicine, Stanford University
    • Scott Leischow, PhD - Professor and Director, Clinical and Translational Science, Arizona State University, Former Senior Advisor for Tobacco Policy at HHS

    Additional details and registration information can be accessed with this link or by visiting the  Achieve website, http://ir.achievelifesciences.com/events-and-webcasts.

    About Achieve and Cytisinicline

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2

    Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

    Media Contact                                 

    Glenn Silver

     

    (646) 871-8485

    Investor Relations Contact

    Jason Wong

     

    (415) 375-3340 ext. 4

    Chantix® is a registered trademark of Pfizer Inc.  

    References

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-host-smoking-cessation-key-opinion-leader-virtual-roundtable-on-november-17th-2020-301160210.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
View All Achieve Life Sciences Inc. News